PMID- 34114739
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210717
IS  - 2578-5745 (Electronic)
IS  - 2578-5745 (Linking)
VI  - 3
IP  - 7
DP  - 2021 Jul
TI  - Comparison of Two Rituximab Induction Regimens for Antineutrophil Cytoplasm 
      Antibody-Associated Vasculitis: Systematic Review and Meta-Analysis.
PG  - 484-494
LID - 10.1002/acr2.11274 [doi]
AB  - OBJECTIVE: The objective of this study was to compare the efficacy and safety of 
      two rituximab (RTX) regimens for the induction of remission in severe 
      antineutrophil cytoplasm antibody-associated vasculitis (AAV): the four-dose (375 
      mg/m(2) intravenously weekly) versus the two-dose (1000 mg intravenously 
      biweekly) regimen. METHODS: A systematic review was performed to identify studies 
      using the four- and/or two-dose RTX regimens for induction of remission in severe 
      AAV. Disease status 6 months after RTX infusion was required for inclusion. 
      Patients were excluded if they received concomitant cyclophosphamide or plasma 
      exchange. The primary end point was the proportion of patients in complete 
      remission at 6 months. The pooled estimate was obtained by using meta-analysis 
      methods for proportions with random effects. Secondary end points included 
      antineutrophil cytoplasm antibody status, number of patients with B-cell 
      depletion, mean prednisone dose, infections, and death. RESULTS: A total of 27 
      studies and 506 patients were included for analysis: 361 patients received the 
      four-dose regimen, and 145 patients received the two-dose regimen. Most patients 
      had relapsing disease at inclusion (83% and 92% of patients, respectively). There 
      was no significant difference between the four- and two-dose regimens, with a 
      complete remission achieved in 85% (95% confidence interval [CI]: 70-96) and 91% 
      (95% CI: 79-99) of patients, respectively. At 6 months, both regimens were 
      associated with a similar mean daily prednisone dose (8.1 mg), infections (12% in 
      both), and death (1% vs 0%, respectively). CONCLUSION: No difference was found in 
      terms of efficacy or safety between the four- and two-dose RTX regimens for 
      induction of remission in severe AAV.
CI  - (c) 2021 The Authors. ACR Open Rheumatology published by Wiley Periodicals LLC on 
      behalf of American College of Rheumatology.
FAU - Benard, Valerie
AU  - Benard V
AD  - Canadian Network for Research on Vasculitides, Hopital Sacre-Coeur de Montreal, 
      and University of Montreal, Montreal, Quebec, Canada.
FAU - Farhat, Cynthia
AU  - Farhat C
AD  - University of Montreal, Montreal, Quebec, Canada.
FAU - Zarandi-Nowroozi, Melissa
AU  - Zarandi-Nowroozi M
AD  - University of Montreal, Montreal, Quebec, Canada.
FAU - Durand, Madeleine
AU  - Durand M
AD  - Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada.
FAU - Charles, Pierre
AU  - Charles P
AD  - National Referral Center for Rare Systemic Autoimmune Diseases, Universite de 
      Paris, and Hopital Cochin, Assistance Publique-Hopitaux de Paris, Paris, France.
FAU - Puechal, Xavier
AU  - Puechal X
AUID- ORCID: 0000-0003-3573-9203
AD  - National Referral Center for Rare Systemic Autoimmune Diseases, Universite de 
      Paris, and Hopital Cochin, Assistance Publique-Hopitaux de Paris, Paris, France.
FAU - Guillevin, Loic
AU  - Guillevin L
AD  - National Referral Center for Rare Systemic Autoimmune Diseases, Universite de 
      Paris, and Hopital Cochin, Assistance Publique-Hopitaux de Paris, Paris, France.
FAU - Pagnoux, Christian
AU  - Pagnoux C
AD  - Canadian Network for Research on Vasculitides, Mount Sinai Hospital, and 
      University of Toronto, Toronto, Ontario, Canada.
FAU - Makhzoum, Jean-Paul
AU  - Makhzoum JP
AUID- ORCID: 0000-0003-4523-8525
AD  - Canadian Network for Research on Vasculitides, Hopital Sacre-Coeur de Montreal, 
      and University of Montreal, Montreal, Quebec, Canada.
LA  - eng
PT  - Journal Article
DEP - 20210611
PL  - United States
TA  - ACR Open Rheumatol
JT  - ACR open rheumatology
JID - 101740025
PMC - PMC8280814
EDAT- 2021/06/12 06:00
MHDA- 2021/06/12 06:01
PMCR- 2021/06/11
CRDT- 2021/06/11 08:53
PHST- 2021/01/08 00:00 [received]
PHST- 2021/04/26 00:00 [accepted]
PHST- 2021/06/12 06:00 [pubmed]
PHST- 2021/06/12 06:01 [medline]
PHST- 2021/06/11 08:53 [entrez]
PHST- 2021/06/11 00:00 [pmc-release]
AID - ACR211274 [pii]
AID - 10.1002/acr2.11274 [doi]
PST - ppublish
SO  - ACR Open Rheumatol. 2021 Jul;3(7):484-494. doi: 10.1002/acr2.11274. Epub 2021 Jun 
      11.